TNKS

Poly [ADP-ribose] polymerase tankyrase-1

91,150 patent compounds predicted against TNKS, 52,159 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL167751	1.00	19/20
SCHEMBL165829	1.00	17/20
SCHEMBL120735	0.54	17/20
SCHEMBL179040	0.71	14/20
SCHEMBL120737	0.61	14/20
SCHEMBL169194	0.64	13/20
Flavone (SCHEMBL110027)	0.84	12/20
SCHEMBL215530	0.64	12/20
SCHEMBL162259	0.53	12/20
SCHEMBL103839	1.00	11/20
SCHEMBL164147	0.54	10/20
Flavone (SCHEMBL18879)	1.00	9/20
SCHEMBL127446	1.00	9/20
SCHEMBL147895	0.50	9/20
SCHEMBL148227	0.50	8/20
SCHEMBL146851	0.49	8/20
SCHEMBL147345	0.73	7/20
SCHEMBL146025	0.60	7/20
SCHEMBL123427	0.59	7/20
SCHEMBL56854	0.54	7/20

Germline variants in TNKS on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full TNKS gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to TNKS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations	PHASE1/PHASE2	COMPLETED
Surgical Pembro +/- Olaparib w TMZ for rGBM	PHASE2	RECRUITING
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP	PHASE2	COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial	PHASE2	RECRUITING
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)	PHASE1/PHASE2	RECRUITING
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer	PHASE1	COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
High Definition Profiling of Ovarian Cancer Ascites	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a TNKS binder may also engage these)

Protein	Name	Similarity
Q6PFX9	—	1.000	Q6PFX9 →
Q3UES3	—	1.000	Q3UES3 →
TNKS2	Poly [ADP-ribose] polymerase tankyrase-2	0.996	landscape →
Q9VBP3	—	0.996	Q9VBP3 →
G5E8K5	—	0.995	G5E8K5 →
Q01484	—	0.994	Q01484 →
Q8C8R3	—	0.993	Q8C8R3 →
O70511	—	0.993	O70511 →
Q02357	—	0.992	Q02357 →
Q12955	—	0.990	Q12955 →
O75179	—	0.990	O75179 →
P16157	—	0.990	P16157 →
Q99NH0	—	0.989	Q99NH0 →
Q5TYM7	—	0.988	Q5TYM7 →
Q65XV2	—	0.988	Q65XV2 →
P51480	—	0.987	P51480 →
Q60772	—	0.987	Q60772 →
Q8IWZ3	—	0.986	Q8IWZ3 →
Q08E43	—	0.986	Q08E43 →
A7E2S9	—	0.986	A7E2S9 →
P25799	—	0.985	P25799 →
KDM1A	Lysine-specific histone demethylase 1A	0.985	landscape →
Q2T9W8	—	0.985	Q2T9W8 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.984	landscape →
Q63618	—	0.984	Q63618 →
Q9VCA8	—	0.984	Q9VCA8 →
Q4R544	—	0.983	Q4R544 →
Q66HD5	—	0.983	Q66HD5 →
B3M301	—	0.983	B3M301 →
KAT8	Histone acetyltransferase KAT8	0.982	landscape →